Dr. Sara M. Tolaney mentioned HER2-positive breast most cancers, highlighting key trials, evolving remedy methods and the potential for improved outcomes.In a presentation...
Findings on golidocitinib with PD-1 antibodies for NSCLC sufferers progressing on anti-PD-1 remedy shall be introduced at ELCC 2025 in Paris this month.Amongst...
Elevation Oncology discontinues EO-3021 for gastric and GEJ cancers after section 1 trial exhibits inadequate efficacy, specializing in advancing EO-1022 as an alternative.Elevation...
